Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Giovanni Guarneri

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9778-6932; OpenAlex author ID A5017119995. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  2. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  3. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-026-09467-z↗
  4. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  5. Prognostic value of preoperative CT scan derived body composition measures in resected pancreatic cancer. Co-author DOI 10.1016/j.ejso.2023.02.005↗
  6. Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma? First author DOI 10.1016/j.dld.2021.04.027↗
  7. Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. Co-author DOI 10.1016/j.ejso.2021.01.001↗
  8. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Co-author DOI 10.3389/fonc.2021.812102↗
  9. Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic can… First author DOI 10.1016/j.ejso.2020.02.013↗
  10. Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm? Co-author DOI 10.4103/eus.eus_61_17↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 10 shared papers, 2017–2026 · strength 1.69
  2. Marina Macchini · 4 shared papers, 2025–2026 · strength 0.88
  3. Stefano Crippa · 6 shared papers, 2017–2024 · strength 0.81
  4. Nicolò Pecorelli · 4 shared papers, 2021–2026 · strength 0.81
  5. Gabriele Capurso · 4 shared papers, 2021–2026 · strength 0.79
  6. Michele Reni · 4 shared papers, 2021–2026 · strength 0.77
  7. Diego Palumbo · 3 shared papers, 2024–2026 · strength 0.67
  8. Giulia Orsi · 3 shared papers, 2025–2026 · strength 0.63
  9. Catia Carconi · 2 shared papers, 2026 · strength 0.45
  10. Francesco DE COBELLI · 2 shared papers, 2024–2026 · strength 0.43
  11. Giulia Gasparini · 3 shared papers, 2020–2024 · strength 0.43
  12. Giuseppe Vanella · 2 shared papers, 2025–2026 · strength 0.41
  13. Stefano Partelli · 3 shared papers, 2020–2021 · strength 0.40
  14. Paolo Giorgio Arcidiacono · 2 shared papers, 2025–2026 · strength 0.40
  15. Domenico Tamburrino · 2 shared papers, 2021–2025 · strength 0.34
  16. Gianpaolo Balzano · 2 shared papers, 2020–2021 · strength 0.24
  17. Claudio Fiorino · 1 shared paper, 2026 · strength 0.23
  18. M. De Vincenzi · 1 shared paper, 2026 · strength 0.23
  19. Anna Fosfuri · 1 shared paper, 2026 · strength 0.22
  20. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.22
  21. Mario Scartozzi · 1 shared paper, 2026 · strength 0.22
  22. Letizia Procaccio · 1 shared paper, 2026 · strength 0.22
  23. Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.22
  24. Silvia Bozzarelli · 1 shared paper, 2026 · strength 0.22
  25. Francesca Bergamo · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.